University of Cambridge Jul 17 2025 Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer's disease drug. They found the drug slowed cognitive decline by 46% in a group of patients with early stage, slow-progressing mild cognitive impairment – a condition that can progress to Alzheimer's. Using AI allowed the team to split trial participants into two groups: either slowly or rapidly progressing towards Alzheimer's disease. They could then look